Cysal GmbH produces arginyl-aspartate and lysyl-aspartate (dipeptides) on an industrial scale by means of an internationally-patented biotechnological process.
The biotechnological company uses these dipeptides, i.e. the bond of two amino acids, as a basis for the production of specially developed end products such as energy tonics, skin creams, fish food or infusion agents. In addition Cysal licences its technology to relevant industrial corporates.
The company was established in 2012 as a spin-off of the Institute for Molecular Microbiology and Biotechnology at the University of Münster (Westfälische Wilhelms-Universität). Dr. Ahmed Sallam, who is also the managing director, founded Cysal together with Dr. Martin Krehenbrink of Oxford University.
The early stage fund Gründerfonds Münsterland, which is managed by eCAPITAL, invested in Cysal in 2012.